by Barry101 | Nov 6, 2023 | Press Release
Highlights AIM’s Significant Momentum and Ongoing Achievement of Clinical and Regulatory Milestones Urges Shareholders to Protect AIM’s Progress by Voting for the Company’s Board of Directors and Discarding Any Proxy Materials from the Activist Group...
by Barry101 | Oct 30, 2023 | Press Release
OCALA, Fla., Oct. 30, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including...
by Barry101 | Oct 17, 2023 | Uncategorized
OCALA, Fla., Oct. 17, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC (“Azenova”), a professional business development (BD) consulting firm, to support efforts to...
by Barry101 | Oct 17, 2023 | Press Release
OCALA, Fla., Oct. 17, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC (“Azenova”), a professional business development (BD) consulting firm, to support efforts to...
by Barry101 | Sep 22, 2023 | Press Release
OCALA, Fla., Sept. 22, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer...